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X -linked hypophosphatemia (XLH) is a rare bone disease affecting an estimated 1:20 000 to 25 000 
individuals. XLH is caused by mutations in PHEX 
whose key consequences include elevations of fibroblast 
growth factor 23 (FGF23) causing renal phosphate 
losses and impairments of vitamin D activation with re-
sultant hypophosphatemic rickets and osteomalacia (1). 
Additional molecular consequences of PHEX deficiency 
(beyond FGF23, hypophosphatemia, and vitamin D me-
tabolism) may contribute to disease features including 
dental abscesses. Conventional medical therapy with 
active forms of vitamin D plus phosphate salts improve 
skeletal deformities in growing children and osteomal-
acia symptoms in adults. Recently anti-FGF23 antibody 
treatment using burosumab has become available.
Although usually diagnosed in childhood, despite 
conventional therapy the lifelong consequences of XLH 
often include short stature, skeletal deformities, sig-
nificant pain, impaired mobility, and disability among 
adults, which impair quality of life (1, 2). Impaired 
mobility begins in childhood, but in adults is largely a 
mechanical consequence of residual lower extremity de-
formities, enthesopathy, and osteoarthritis, along with 
bone pain from osteomalacia and pseudofractures. 
About 50% of adults with XLH had active fractures or 
pseudofractures (3). Enthesopathy affects nearly 100% 
of adults with XLH eventually, increasing with age (3-5). 
Enthesopathy begins with the calcification of tendon 
and ligament insertion sites but progresses to develop-
ment of osteophytes, often bridging between adjacent 
bones (4-6). Enthesopathy is usually bilateral and pre-
dominantly affects weight bearing joints and the spine, 
where it can cause spinal stenosis. Enthesopathy is not 
known to be prevented by, or responsive to, any medical 
therapy. Osteoarthritis is highly prevalent in adults with 
XLH, affecting 63% (3) and beginning at younger ages 
than in the general population. Osteoarthritis is most 
likely a consequence of lifelong abnormal mechanical 
loading of joints resulting from the skeletal deformities 
remaining from childhood.
In this issue, Steele et al. performed detailed skeletal 
and functional assessments in a cross-sectional study 
of 9 adults younger than age 60 years with XLH (6). 
Ambulatory subjects were selected having self-reported 
functional disability. Thus, subjects without reported 
disability, and hence more mild disease, were excluded. 
On the other hand, subjects with extreme disability 
causing inability to walk at least 200 feet were also ex-
cluded. This study was small and did not encompass 
the full the range of mobility and function of adults 
with XLH, and hence could not estimate the prevalence 
of dysfunction. However, the detailed measurements 
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provide important insights into the features influencing 
mobility among adults with XLH.
All participants reported bone and joint pain. 
Radiographic evidence of osteoarthritis and 
enthesopathy were extensive, affecting all major joints 
of the upper and lower extremities. Enthesopathy 
throughout the spine included the anterior and pos-
terior spinal ligaments. Most had kyphosis and scoliosis. 
Osteoarthritis and enthesopathy were especially prom-
inent around the pelvic girdle, along with flattening of 
the femoral head, coxa vara, and bowing of the femur 
shaft. These features are commonly reported in XLH, 
though the extent of radiographic involvement in these 
adults is notable when considering the disability associ-
ated with this disease.
Balance scores and strength on manual motor testing 
were normal, but scores on a patient reported lower ex-
tremity functional scale were significantly lower than 
controls. Passive range of motion was limited at the hip, 
knee, and ankle. Cervical spine extension was impaired, 
whereas flexion was spared. These findings have conse-
quences for mobility and gait.
This was the first study to report kinematic gait ana-
lysis to characterize gait abnormalities in XLH using 
reflective markers over bony landmarks and video-
recording subjects as they walked. Joint angles during 
gait were smaller in XLH subjects consistent with the 
passive range of motion testing. The rigidity of the spine 
resulting from enthesopathy corresponded to a more 
flexed position throughout the gait cycle and a fixed 
stooped posture. XLH subjects had greater bilateral 
sway of the trunk, whereas limitations in hip and knee 
extension resulted in shorter steps. Altogether, these in-
dividual abnormalities quantitatively characterize the 
classic waddling gait of XLH.
This study moved from the radiographic description 
of osteoarthritis and enthesopathy in adults with XLH 
to quantitate their impact on range of motion and gait, 
which, along with pain, are critical to function for ac-
tivities of daily living. Abnormal joint motions during 
gait may further contribute to pain, arthritis, and 
dysmobility in an ongoing cycle. Further, the upper ex-
tremity findings would result in additional compromise 
of activities of daily living beyond those involving sit-
ting, standing, and walking.
Further studies are needed to establish the timing and 
rate of progression of enthesopathy. Connor et al. quan-
tified enthesopathy by listing number of affected sites, 
and found there was no apparent effect of proportion of 
time treated with conventional therapy (4). However, this 
method does not account for differences in the amount of 
enthesopathy at an individual location. A reliable method 
is needed to quantify enthesopathy and osteophytes both 
in the individual bony locations and in the total patient.
Mouse models suggested that FGF23 itself might be dir-
ectly involved in enthesopathy and that mineralization of 
entheses might be exacerbated by treating with calcitriol 
and phosphate (5, 7). Although this suggests that strat-
egies to block the effects of FGF23 hypothetically could 
be beneficial, there are no studies in mice or humans ad-
dressing this question. Specifically, there currently are no 
data to determine whether anti-FGF23 antibody therapy 
(such as with burosumab) might have any effect to slow 
the progression of enthesopathy. In a placebo controlled 
trial in 134 adults with XLH, burosumab improved self-
reported ratings of stiffness and physical function, but no 
difference between groups was seen for the 6-minute walk 
distance after 24 weeks, possibly because of the pervasive 
osteoarthritis and enthesopathy and the relatively short 
time frame, though in the extension study with all subjects 
receiving burosumab, by week 48, subjects had increased 
6-minute walk distance (3).
In a randomized controlled trial, 61 children with 
XLH and having persistent rickets despite conven-
tional therapy had improvements in rickets severity 
and lower limb deformity when switched to treatment 
with burosumab compared with ongoing conventional 
therapy (8). Improvements of lower limb deformity might 
decrease risk for osteoarthritis. However, the full magni-
tude of impact of burosumab during the growing years is 
not known. Pediatric trials of burosumab were limited to 
children between the ages of 1 and 12 at enrollment and 
mostly enrolled prepubertal children. Clinical trials have 
not assessed the effects of burosumab during puberty or 
during the transition to adulthood. Few children have 
been treated through pubertal completion and none for 
the full duration from infancy to the end of the growth 
period. Consequently, the magnitude of potential effect 
and advantage over conventional therapy on lower limb 
deformity and hence the mechanical effect on joints as 
patients enter adulthood is not yet known.
Currently, adequate evidence is lacking to support 
the best physical treatment approaches (eg, physical 
or occupational therapy, surgical approaches, etc.) to 
enthesopathy and osteoarthritis in adults with XLH. In 
addition, the effects of novel medications for XLH on 
enthesopathy or osteoarthritis have not been assessed. 
It is important to be able quantitate the disease burden 
of adults with XLH and the underlying mechanical ab-
normalities involved so that the effects of medical or 
nonmedical interventions can be assessed. Enthesopathy 
and osteoarthritis develop gradually over the course of 
many years. Years of treatment, along with appropriate 
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whether new treatment options impact development of 
these features.
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